Our Story

The constant commitment of resources and talent in research, winning strategic choices, the quality of execution and the excellence of our specialty solutions qualify us as one of the most important players in diagnostics worldwide.

With a distinctive managerial character and a vision capable of designing future markets and opportunities in the present, we strategically interpret the evolution of the diagnostic world, remaining faithful to our mission as “Diagnostic Specialists.”

50 years serving
doctors and patients

1968

Foundation of SORIN, center for the production of nuclear energy in Saluggia (Vercelli province), by a joint venture between FIAT and Montecatini.
The first European in vitro diagnostic center came to be.

1997

Diasorin, the diagnostic division of the SORIN group, is sold to the multinational American Standard International.

2000

Diasorin returns to Italian hands through a Management Buyout operation.

2007

On July 19, 2007, trading in Diasorin shares opened on the Italian Stock Exchange.

2010/15

Diasorin continues to grow both in-house and beyond, by expanding worldwide and investing in technology and product innovation. Numerous partnerships have been signed with the major players in the world of diagnostics (Roche, Beckman Coulter, and Meridian Bioscience).

2016

Diasorin enters the molecular diagnostics sector through the acquisition of the US company Focus Diagnostics, today Diasorin Molecular, providing the Group with further expertise and excellence.

2018

Diasorin joins the FTSE MIB index.
Diasorin signs a partnership with Qiagen for the testing of latent tuberculosis and acquires the ELISA business of Siemens Healthineers.

2020

Efforts and investments focus on COVID-19. Four tests are launched to diagnose the disease, followed by a fifth in January 2021.
Diasorin signs an exclusive license agreement with TTP for the development of a Point-of-Care (POC) molecular solution.

2021

Diasorin launches the LIAISON IQ analyzer with Lumos Diagnostics for the immunodiagnostics POC.
Diasorin acquires the US company Luminex Corporation for $1.8 billion, acquiring multiplex molecular diagnostics technology and Licensed Technologies.
Diasorin launches the Lyme test in partnership with QIAGEN and the MeMed BV^® test in partnership with MeMed.

2022

Diasorin launches molecular reagents for the monkeypox virus.
Diasorin continues its collaboration with BARDA to support the clinical validation and FDA 510(k) authorization of LIAISON^® NES.
DiaSorin and B·R·A·H·M·S work together on a new immunodiagnostic solution to improve patient care.

From 2000 to 2010: the CLIA market

The focus on immunodiagnostics has characterized the company since its origins, but in 2000 a business strategy was developed to raise the company's profile in comparison with the major players in the market. Over a decade, from 2000 to 2010, we focused on specialty and niche products where innovation was key.
This journey was taken in parallel with a significant technological step: in the immunodiagnostics market, modern CLIA technology replaces the older RIA and ELISA.
In this context, DiaSorin acquired the rights to use the LIAISON^® platform, which can read the extensive test menu developed over the years.
Within a decade, we became able to offer the widest CLIA specialty test menu on the market, on fully automated platforms.

From 2010 to 2019: strategic partnerships

The strategic choices made over the previous decade ensured us constant and continuous growth in various areas: we improved our range of tests and production technologies, acquired new types of customers, entered new market segments and strengthened our global commercial presence.
With such a dynamic and specialized profile, we have become a strategic partner for some of the major players in diagnostics worldwide, such as Roche, Beckman Coulter, Meridian Bioscience and QIAGEN. In particular, we entered into a partnership with the latter to develop an innovative solution to screen for latent tuberculosis, one of the most common infectious diseases in the world.
With the acquisition of the US company Focus Diagnostics, now DiaSorin Molecular, we entered the molecular diagnostics sector, a crucial step in light of the 2020 events relating to the pandemic.

2020, 2021, 2022: new markets and new contacts

The COVID-19 pandemic, which had a major impact on our business in 2020, resulted in significant changes in the world of diagnostics. It let to a strategic reflection on our potential for growth, towards new markets and new types of customers.
First, COVID accelerated the process of the decentralization of diagnostics, highlighting the need to provide patients with diagnostic results increasingly rapidly, by means of simple and cost-effective solutions.
With this in mind, we signed an exclusive license agreement with the British company TTP for the creation of a Point-of-Care (POC) molecular solution, i.e. in close proximity to the patient, on which to use our diagnostic solutions.
In addition, with the acquisition of Luminex, we expanded our offer in the field of molecular diagnostics, equipping it with multiplex technology (with the ability to analyze, in a single diagnostic cycle, multiple parameters starting from a single biological sample) and enter the Life Sciences sector, an area that is laying the foundations for major new collaborations and business opportunities.